An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients with IgA Nephropathy Who Have Completed Study Nef-301 in China
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Budesonide (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Everest Medicines
Most Recent Events
- 12 Nov 2024 Status changed from active, no longer recruiting to completed.
- 28 Aug 2024 According to Everest Medicines media release, topline results from open label study of NEFECON in China, are expected in 2H 2024.
- 27 Mar 2024 According to Everest Medicines media release, the company expect to report results in 3Q 2024.